Back

L&C Bio wins Peru approval for injectable human-skin ECM product Re2O

Verifying
  • L&C Bio secured Peruvian regulatory approval for local sales of human-skin ECM product Re2O.
  • DIGEMID approved Re2O on September 11, allowing formal local commercialization in Peru.
  • L&C Bio plans Latin American expansion and is pursuing approvals in several overseas markets.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.